Capital Investment Advisors LLC Increases Holdings in Johnson & Johnson $JNJ

Capital Investment Advisors LLC grew its holdings in Johnson & Johnson (NYSE:JNJ) by 1.3% during the third quarter, according to the company in its most recent filing with the SEC. The fund owned 440,082 shares of the company’s stock after acquiring an additional 5,517 shares during the quarter. Johnson & Johnson comprises 1.3% of Capital Investment Advisors LLC’s investment portfolio, making the stock its 14th biggest holding. Capital Investment Advisors LLC’s holdings in Johnson & Johnson were worth $81,600,000 as of its most recent SEC filing.

Several other institutional investors have also recently added to or reduced their stakes in the business. Planned Solutions Inc. boosted its holdings in Johnson & Johnson by 2.8% in the third quarter. Planned Solutions Inc. now owns 4,266 shares of the company’s stock valued at $791,000 after purchasing an additional 118 shares in the last quarter. Sound Financial Strategies Group LLC acquired a new position in shares of Johnson & Johnson in the 3rd quarter valued at $210,000. Core Wealth Management Inc. purchased a new position in shares of Johnson & Johnson in the 3rd quarter valued at $226,000. Nisa Investment Advisors LLC raised its stake in Johnson & Johnson by 32.9% during the 3rd quarter. Nisa Investment Advisors LLC now owns 954,381 shares of the company’s stock worth $176,961,000 after acquiring an additional 236,029 shares in the last quarter. Finally, Next Level Private LLC lifted its position in Johnson & Johnson by 1.6% in the third quarter. Next Level Private LLC now owns 3,852 shares of the company’s stock valued at $725,000 after acquiring an additional 60 shares during the last quarter. Hedge funds and other institutional investors own 69.55% of the company’s stock.

Johnson & Johnson Trading Up 2.6%

NYSE:JNJ opened at $209.79 on Tuesday. Johnson & Johnson has a 12-month low of $141.50 and a 12-month high of $215.18. The company has a current ratio of 1.07, a quick ratio of 0.80 and a debt-to-equity ratio of 0.50. The stock’s 50 day simple moving average is $203.34 and its 200-day simple moving average is $185.38. The firm has a market cap of $505.45 billion, a P/E ratio of 20.25, a PEG ratio of 2.10 and a beta of 0.34.

Johnson & Johnson (NYSE:JNJ) last announced its quarterly earnings data on Wednesday, August 30th. The company reported $2.26 EPS for the quarter. Johnson & Johnson had a net margin of 27.26% and a return on equity of 32.73%. The company had revenue of $24.02 billion during the quarter. Equities analysts anticipate that Johnson & Johnson will post 10.58 EPS for the current year.

Johnson & Johnson Announces Dividend

The firm also recently disclosed a quarterly dividend, which will be paid on Tuesday, March 10th. Shareholders of record on Tuesday, February 24th will be issued a $1.30 dividend. This represents a $5.20 dividend on an annualized basis and a yield of 2.5%. The ex-dividend date of this dividend is Tuesday, February 24th. Johnson & Johnson’s payout ratio is currently 50.19%.

Analyst Upgrades and Downgrades

Several brokerages have issued reports on JNJ. Stifel Nicolaus raised their price objective on Johnson & Johnson from $165.00 to $190.00 and gave the stock a “hold” rating in a report on Wednesday, October 15th. Daiwa Capital Markets raised Johnson & Johnson from a “neutral” rating to an “outperform” rating and set a $203.00 target price for the company in a research report on Monday, October 20th. Wolfe Research lifted their price target on Johnson & Johnson from $225.00 to $240.00 and gave the stock an “outperform” rating in a research report on Monday, January 5th. Barclays increased their price objective on Johnson & Johnson from $197.00 to $217.00 and gave the company an “equal weight” rating in a report on Tuesday, December 30th. Finally, Cowen reaffirmed a “buy” rating on shares of Johnson & Johnson in a report on Tuesday, October 14th. Four research analysts have rated the stock with a Strong Buy rating, fifteen have assigned a Buy rating and nine have given a Hold rating to the company’s stock. According to MarketBeat.com, the company has an average rating of “Moderate Buy” and an average price target of $213.33.

About Johnson & Johnson

Johnson & Johnson is a multinational healthcare company headquartered in New Brunswick, New Jersey, that develops, manufactures and markets a broad range of products across pharmaceuticals, medical devices and previously consumer health. Founded in 1886 by the Johnson family, the company has grown into a global healthcare organization with operations and sales in many countries around the world.

The company’s pharmaceuticals business, organized largely under its Janssen research and development organization, focuses on prescription medicines across therapeutic areas such as immunology, infectious disease, oncology and neuroscience.